Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study

PURPOSE: The effect of high-dose imatinib (800 mg/day) on survival in the adjuvant treatment of patients with resected KIT exon 9–mutated gastrointestinal stromal tumors (GIST) is not established. Here, the association of dose and other clinicopathologic variables with survival was evaluated in a la...

Descripción completa

Detalles Bibliográficos
Autores principales: Vincenzi, Bruno, Napolitano, Andrea, Fiocco, Marta, Mir, Olivier, Rutkowski, Piotr, Blay, Jean-Yves, Reichardt, Peter, Joensuu, Heikki, Fumagalli, Elena, Gennatas, Spyridon, Hindi, Nadia, Nannini, Margherita, Spalato Ceruso, Mariella, Italiano, Antoine, Grignani, Giovanni, Brunello, Antonella, Gasperoni, Silvia, De Pas, Tommaso, Badalamenti, Giuseppe, Pantaleo, Maria A., van Houdt, Winan J., IJzerman, Nikki S., Steeghs, Neeltje, Gelderblom, Hans, Desar, Ingrid M.E., Falkenhorst, Johanna, Silletta, Marianna, Sbaraglia, Marta, Tonini, Giuseppe, Martin-Broto, Javier, Hohenberger, Peter, Le Cesne, Axel, Jones, Robin L., Dei Tos, Angelo P., Gronchi, Alessandro, Bauer, Sebastian, Casali, Paolo G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365355/
https://www.ncbi.nlm.nih.gov/pubmed/34615721
http://dx.doi.org/10.1158/1078-0432.CCR-21-1665

Ejemplares similares

Ejemplares similares